/
Hematology
Von Willebrand Disease
14
Pipeline Programs↗
15
Active Trials↗
10
Companies Involved↗
Von Willebrand disease is an emerging landscape with 14 programs across 10 companies. The most active players are Takeda, Roche, Vega Therapeutics, Inc. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 1
No programs
Phase 35
Approved
No programs
Analysis
Trial Status
39
clinical trials
Completed18 · 46%
Recruiting12 · 31%
Terminated4 · 10%
Active, not recruiting2 · 5%
Available1 · 3%
Not yet recruiting1 · 3%
Other1 · 3%
Clinical Trials
Trial Activity
39 trials
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)
Recruiting·—·Preclinical·NCT06754852·108 enrolled
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Recruiting·BBleeding and Clotting Disorders Institute Peoria, Illinois·Phase 1·NCT05500807·40 enrolled
Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
Not yet recruiting·—·N/A·NCT07410130·25 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)